Loteprednol Etabonate

In these videos, Preeya K. Gupta, MD, FACS, associate professor of ophthalmology at Duke University, talks about the various treatment options for dry eye, both approved and in the pipeline, as well as challenges in diagnosis.

LAS VEGAS — In this Healio Video Perspective from Eyecelerator@ASCRS, Edward J. Holland, MD, discusses Eysuvis (loteprednol etabonate ophthalmic suspension 0.25%, Kala Pharmaceuticals) and its utility for patients with dry eye disease.

WAILEA, Hawaii — In this video from Hawaiian Eye 2021, Todd Bazemore, chief operating officer at Kala Pharmaceuticals, offers a company update, including the recent approval of Eysuvis (loteprednol) for dry eye disease signs and symptoms.

An 81-year-old woman presented to New England Eye Center for a scheduled glaucoma follow-up. She reported blurry vision and pain in her right eye and ongoing chronic itching in both eyes. She denied headache, nausea or vomiting.

I frequent a few groups on Facebook and Twitter dedicated to dry eye disease. Not a day goes by without several inquiries about starting to treat DED patients.

In this video perspective from the virtual AAO annual meeting, Edward J. Holland, MD, discusses clinical trial data for Eysuvis (KPI-121 0.25%; loteprednol etabonate ophthalmic suspension, Kala), which was recently approved by the FDA.

In this video, Cynthia A. Matossian, MD, interviews Darrell E. White, MD, about the potential impact of Eysuvis (loteprednol etabonate, Kala Pharmaceuticals), recently approved for the short-term treatment of the signs and symptoms of dry eye disease, including flares.

“I quiver with fear.”

“There ain’t no cure for the summertime blues.”

Consistent and comprehensive communication between optometrists and ophthalmologists will always be the key to successful comanagement of cataract patients.